Lombard Medical Technologies PLC Live case demonstration at iCON 2014

TIDMLMT

Lombard Medical Technologies PLC

13 February 2014

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Live Case of Challenging AAA Repair Using Aorfix(TM) Highlighted at iCON 2014

London, UK and Irvine, CA 13 February, 2014 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic aneurysms ("AAAs"), announces that on Tuesday, February 11, a team of surgeons led by Venkatesh Ramaiah, M.D. of The Arizona Heart Institute in Phoenix, AZ. successfully performed a live case demonstration of a challenging AAA repair using Aorfix(TM), the Company's flexible endovascular stent graft, to more than 150 physicians at iCON 2014, a meeting of the International Society of Endovascular Specialists in Phoenix, AZ.

During the procedure, which was broadcast live from The Arizona Heart Hospital in Phoenix, a panel of prominent vascular surgeons engaged in a dialogue with the surgical team focused on the deployment and placement of the Aorfix device during the AAA procedure. The panel was chaired by Edward Diethrich, M.D., the Program Chairman.

Aorfix is the only AAA stent graft approved in the U.S. and Europe for the treatment of patients with neck angulations up to and including 90 degrees. The live case patient's AAA had an approximate 65 degree aortic angulation.

Simon Hubbert, Chief Executive Officer of Lombard Medical, commented: "The International Society of Endovascular Specialists includes a number of the world's leading vascular surgeons and provides an excellent platform to demonstrate Aorfix, which is designed to treat complex anatomies. Live cases provide a unique opportunity to help educate physicians on use of technology and we are delighted that we could be a part of the live case program at iCON 2014."

Dr. Ramaiah commented: "I believe that having an approved on-label option for patients with high angle neck anatomies is a significant step forward in the treatment of AAA cases. Until Aorfix, these patients were treated with EVAR devices not approved for use in high angle neck anatomies, which could lead to serious complications and poorer patient outcomes."

For further information:

 
 Lombard Medical Technologies PLC       Tel: +44 (0)1235 750 800 
  Simon Hubbert, Chief Executive 
  Officer 
  Ian Ardill, Chief Financial Officer 
 
 FTI Consulting (UK)                    Tel: +44 (0)20 7831 3113 
  Simon Conway / Stephanie Cuthbert 
  / Victoria Foster Mitchell 
 
 Allen & Caron (US)                       Tel: +1 (949) 474 4300 
  Matt Clawson

About International Society of Endovascular Specialists

The International Society of Endovascular Specialists (ISES) is dedicated to enhancing global research, education and clinical expertise in the treatment of one of the world's number one killers - vascular disease. Using innovative technologies and interventional techniques ISES strives to improve patient care throughout the world.

About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year over 500,000 new cases are diagnosed. In the US, aortic aneurysm disease is among the leading causes of death and it is estimated that 1.7 million people over the age of 55 have an abdominal aortic aneurysm.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company focused on device solutions for the abdominal aortic aneurysm ("AAA") repair market. The Company's lead product, Aorfix(TM), is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. Aorfix is the only stent graft approved for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide. Aorfix is the first AAA stent graft not of US origin to gain US FDA approval. The Company is headquartered in Oxfordshire, England with US operations in Irvine, CA.

Further background on the Company can be found at www.lombardmedical.com.

FORWARD-LOOKING STATEMENTS

This announcement may contain forward-looking statements that reflect the Company's current expectations regarding future events, including the commercialization and regulatory clearance of the Company's products, the Group's liquidity and results of operations, as well as the Group's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's research and development and commercialization strategies, the uncertainties related to the regulatory process and the acceptance of the Company's products by hospitals and other medical professionals.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGLGDDBDBBGSX

Lombard Medical Technologies (LSE:LMT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024